Katerina S. Tatarinova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katerina S. Tatarinova has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aleksei Aleksandrovich Titov
A. N. Nesmeyanov Institute of Organoelement Compounds
1 shared publication - Alexander M. Maksimov
Vorozhtsov Novosibirsk Institute of Organic Chemistry
1 shared publication - Alexander S. Novikov
Infochemistry Scientific Center, ITMO University, Saint Petersburg 191002, Russia
1 shared publication - Alexey N. Kuznetsov
Department of Chemistry, Lomonosov Moscow State University, Leninskie gory 1-3, 119991 Moscow, Russia
1 shared publication - Alexey S. Berezin
Nikolaev Institute of Inorganic Chemistry
1 shared publication - Daniil Zhuravlev
Nikolaev Institute of Inorganic Chemistry
1 shared publication
Latest Publications
- Open Access
- 11 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Metastable phases as a route to silver thiolates processing: structural, spectroscopy and computational data
The recent advancements in 11 group metal-organic chalcogenolates (MOCs) based materials raise questions about the preparation of MOC films. In this research, we demonstrate that polymeric [Ag(S-Arf)]n (Arf = perfluorinated aryl group) can be dissolved in pyridine and its homologues (py-R). These solutions can be used to process [Ag(S-Arf)]n using different methods. Crystallization from these solutions produces a new type of MOCs, [(py-R)Ag(S-Arf)]n, that are here systematically characterized by structural, spectroscopic, and computational techniques.
- 11 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMetastable phases as a route to silver thiolates processing: structural, spectroscopy and computational data
The recent advancements in 11 group metal-organic chalcogenolates (MOCs) based materials raise questions about the preparation of MOC films. In this research, we demonstrate that polymeric [Ag(S-Arf)]n (Arf = perfluorinated aryl group) can be dissolved in pyridine and its homologues (py-R). These solutions can be used to process [Ag(S-Arf)]n using different methods. Crystallization from these solutions produces a new type of MOCs, [(py-R)Ag(S-Arf)]n, that are here systematically characterized by structural, spectroscopic, and computational techniques.
- Open Access
- 23 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9262
NanoDeNovo: De Novo Design of Anti-Poliovirus I Sabin Strain Nanobodies by Semi-Automated Computational Pipeline
Despite global vaccination efforts, poliomyelitis continues to cause paralytic cases, highlighting the need for alternative therapeutic approaches. Nanobodies offer significant advantages over conventional antibodies due to their small size, stability, and low immunogenicity, yet few have been developed specifically against poliovirus. This study presents a fully computational pipeline for de novo design of nanobodies targeting Virus Protein 3 (VP3) of the Poliovirus I Sabin strain. Our integrated approach employed Ig-VAE for scaffold generation, ProteinMPNN and RFantibody for sequence design, tFold-Ab/Ag for structure prediction, multi-platform molecular docking (Rfantibody, Rosetta3, ClusPro2, ReplicaDock 2.0), molecular dynamics simulations, and humanization tools. The pipeline identified three humanized nanobodies (scFv-0389-304-6H, scFv-0389-459-5H, and scFv-0743-166-7/H) that demonstrated strong binding to VP3 with binding free energies of −37.66 ± 10.35, −40.11 ± 20.01, and −48.62 ± 11.21 kcal/mol, respectively. All designs exhibited favorable physicochemical properties and high solubility. Notably, nanobodies humanized prior to CDR-loop design (scFv-0743-166-7/H) showed superior stability, binding affinity, and structural similarity to experimentally validated nanobodies. This work demonstrates the feasibility of a fully computational approach for designing promising nanobodies against viral targets, providing an alternative to traditional methods with potential applications in drug design.
- 23 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9262
Open AccessNanoDeNovo: De Novo Design of Anti-Poliovirus I Sabin Strain Nanobodies by Semi-Automated Computational Pipeline
Despite global vaccination efforts, poliomyelitis continues to cause paralytic cases, highlighting the need for alternative therapeutic approaches. Nanobodies offer significant advantages over conventional antibodies due to their small size, stability, and low immunogenicity, yet few have been developed specifically against poliovirus. This study presents a fully computational pipeline for de novo design of nanobodies targeting Virus Protein 3 (VP3) of the Poliovirus I Sabin strain. Our integrated approach employed Ig-VAE for scaffold generation, ProteinMPNN and RFantibody for sequence design, tFold-Ab/Ag for structure prediction, multi-platform molecular docking (Rfantibody, Rosetta3, ClusPro2, ReplicaDock 2.0), molecular dynamics simulations, and humanization tools. The pipeline identified three humanized nanobodies (scFv-0389-304-6H, scFv-0389-459-5H, and scFv-0743-166-7/H) that demonstrated strong binding to VP3 with binding free energies of −37.66 ± 10.35, −40.11 ± 20.01, and −48.62 ± 11.21 kcal/mol, respectively. All designs exhibited favorable physicochemical properties and high solubility. Notably, nanobodies humanized prior to CDR-loop design (scFv-0743-166-7/H) showed superior stability, binding affinity, and structural similarity to experimentally validated nanobodies. This work demonstrates the feasibility of a fully computational approach for designing promising nanobodies against viral targets, providing an alternative to traditional methods with potential applications in drug design.